Precision Medicine in Cancer Therapy

Part I: Individual types of cancer precision medicine, Hematological malignancies.- Lung cancer.- Breast cancer.- Rare malignancies.- Part II: Currently available techniques, Immunohistochemistry enabled precision medicine.- Genomics enabled precision medicine.- Proteomics enabled precision medicine.-  Metabolomics enabled precision medicine, Part III: Future precision medicine.- Imaging precision medicine.- Single cell sequencing in precision medicine.- Microbiome in precision medicine.- Perspectives on precision medicine.

Daniel Von Hoff is a physician scientist whose major interest is the development of new anticancer agents, in both clinic and laboratory settings. He played a pivotal role in the development of many of the anticancer agents now being used routinely. He also pioneered the application of genomics profiling in the clinical care of patients with cancer. Dr. Von Hoff is a former member of the FDA's Oncology Drug Advisory Committee (ODAC) and served on President Bush's National Cancer Advisory Board. He is a former president of the American Association of Cancer Research (AACR) and a past member of the Board of Scientific Advisors of the National Cancer Institute, as well as a former board member of the American Society of Clinical Oncology (ASCO).
Haiyong Han is a tumor biologist with a major interest in targeted drug discovery. He has more than 20 years of experience in preclinical drug development for cancers, particularly pancreatic cancer. His major areas of expertise include the identification and validation of drug targets and biomarkers, lead identification and optimization, and preclinical evaluation and development. Dr. Han has published more than 70 peer reviewed articles and was an inventor on 15 patents/patent applications.